Albany, NY -- (SBWIRE) -- 10/30/2018 -- DelveInsight has announced the addition of the "Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Oral Mucositis for the G8 Countries markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) Japan and China. The Report covers the overview, treatment practice and Oral Mucositis forecasted epidemiology from 2018 to 2027 segmented by G8 Countries markets.

Request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Oral-Mucositis---Market-Insight,-Epidemiology-and-Market-Forecast---2027

Oral mucositis is a common complication of radiotherapy to the head and neck region, chemotherapy and the combination of the two such as seen in conditioning regiments for homologous stem cell transplantation (HSCT). It is often a dose limiting toxicity prohibiting the patient from receiving optimal therapy. It is characterized by oral erythema, ulceration and pain and can predispose to septicemia in the case of neutropenic patients.

DelveInsight estimates suggest that there were ~ 5,333,193 diagnosed incident cases of Oral Mucositis in 2016 in G8 Countries. These diagnosed incident cases are further expected to increase by 2027. Among all G8 countries, the United States had the highest OM associated 1,932,531 cases followed by China and Germany, with a diagnosed incident population of 1,215,921 and 553,145 respectively in 2016. Total grade specific diagnosed incident population of Oral Mucositis includes Grade I 1,669,289 Cases, 2,175,943 Grade II Cases, 1,333,298 Grade III Cases and 154,663 Grade IV Cases in 2016 in G8 Countries. Oral Mucositis associated with Hematopoietic Stem Cell Transplantation may reach 50,939 cases by 2027 in G8 Countries pain and can predispose to septicemia in the case of neutropenic patients.

According to DelveInsight, Head and Neck Cancer treatment associated Oral Mucositis cases were 194,176 in 2016, and projected to increase significantly in upcoming years, owing to the growing incident cases of Head and Neck Cancer and so is the frequency of chemo-radiation therapy for its treatment.

Market analysis carried out for the period of 2016-2027 demonstrates that the Market size of Oral Mucositis was found to be USD 638.8 Million in 2016 in G8 Countries for the forecasted period (2018-2027).

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan
4. China

Study Period: 2016-2027
Drug Companies

1. Enzychem Lifesciences Corporation
2. Soligenix Inc.
3. Otsuka Pharmaceuticals
4. EpicentRx
5. Oragenics, Inc.
And many others

Drugs covered 1. EC-18
2. SGX942
3. OPC-12759
4. RRx-001
5. AG013
And many others

Report Scope The report covers a descriptive overview of the Oral Mucositis, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Oral Mucositis and its treatment in the G8 Countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK) Japan & China. Additionally, an all-inclusive account of both the current and emerging therapies for Oral Mucositis are provided, along with assessment of the impact new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Oral Mucositis market is included in the report, covering drug outreach in G8 Countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Oral Mucositis market